This study is currently not recruiting participants.

A Phase 3 Multicenter Open-Label Extension Trial of Oral RPC 1063 as Therapy for Moderate to Severe Ulcerative Colitis

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

The purpose of this study is to see whether RPC1063 (referred to as the ?study drug? from now on) is safe and effective for the possible treatment of UC. To do this, a comparison will be made between patients who receive study drug and patients who receive placebo (a ?dummy treatment? that looks like the study drug but contains no active ingredient). The purpose of this phase III study is to confirm preliminary results from phase II studies that suggest that the study drug is safe and effective.

Description

The purpose of this study is to see whether RPC1063 (referred to as the ?study drug? from now on) is safe and effective for the possible treatment of UC. To do this, a comparison will be made between patients who receive study drug and patients who receive placebo (a ?dummy treatment? that looks like the study drug but contains no active ingredient). The purpose of this phase III study is to confirm preliminary results from phase II studies that suggest that the study drug is safe and effective.

Details
Condition ulcerative colitis
Age 18years - 75years
Clinical Study IdentifierTX7515
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.